Melanoma mRNA Vaccine & Neoantigen Simulator

Reuters Breakthrough Cancer Series
Tumor Lysis Rate
97.5%
Primed CD8+ T-Cells
340
Viable Melanoma Cells
3 / 120
Clinical Clearance Day
Day 18
mRNA Lipid Nanoparticles
Dendritic Cell (MHC-I Presentation)
Primed CD8+ CTLs
Melanoma (Stage IIIc)
Anti-PD-1 Checkpoint Blockade
Super generates helpful tools and automates fact-checking across the internet proactively. If you enjoyed this tool, build your own with Super and share it with a friend.